Professor David Price
Chair of Primary Care Respiratory Med
- About
-
- Email Address
- d.price@abdn.ac.uk
- Telephone Number
- +44 (0)1224 437237
- School/Department
- School of Medicine, Medical Sciences and Nutrition
- Publications
-
Page 1 of 93 Results 1 to 10 of 923
Novel insights into the comorbidity burden of severe asthma in Canada: Analysis of the Canadian Severe Asthma Registry
The ERS Congress 2025, PA3635Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1183/13993003.congress-2025.PA3635
Derivation and definitions of clinical study variables for multiple long term conditions in patients with chronic obstructive pulmonary disease: Protocol for a modified Delphi methods and consensus study on behalf of the International Cardiovascular and Respiratory Alliance
Pragmatic and Observational Research, vol. 16, pp. 243—251Contributions to Journals: ArticlesEconomic burden of asthma multimorbidity in Singapore: Shadow costs of steroid use
World Allergy Organization Journal, vol. 18, no. 12, 101146Contributions to Journals: ArticlesAre adults with COPD in Australian primary care at a greater risk of cardiovascular events than adults without COPD?
The ERS Congress 2025, PA1398Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1183/13993003.congress-2025.PA1398
A time-clocked care pathway on severe asthma: A global consensus by Delphi methodology
The ERS Congress 2025, PA1414Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1183/13993003.congress-2025.PA1414
Clinical profile of severe asthma (SA) patients Mexican vs Global data and evolution once in the international severe asthma registry (ISAR)
The ERS Congress 2025, PA5707Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1183/13993003.congress-2025.PA5707
Extrafine beclometasone/formoterol is non-inferior to budesonide/formoterol as maintenance and reliever therapy (MART) for adult asthma patients and reduces the total carbon footprint of all inhaler-related greenhouse gas (GHG) emissions
The ERS Congress 2025, PA342Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1183/13993003.congress-2025.PA342
Long-term exacerbation trends before/after initiating triple therapy for uncontrolled asthma
The ERS Congress 2025, PA4637Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1183/13993003.congress-2025.PA4637
Modelling the impact of earlier biologic initiation in severe asthma patients
The ERS Congress 2025, PA1387Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1183/13993003.congress-2025.PA1387
Predicting long-term remission with benralizumab in severe eosinophilic asthma (SEA): Post-hoc analysis of SIROCCO, CALIMA, BORA
The ERS Congress 2025, PA2486Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1183/13993003.congress-2025.PA2486